Tagged Articles

blood transfusions 4 articles

Hospira recalls electrolyte solution due to possible contamination

Hospira is recalling containers of sodium chloride injection used as a source of water and electrolytes for patients with various conditions. The recall is based on a confirmed customer report in which four individual flexible containers of the solution were found to be contaminated with polyester fiber, nylon fiber, cotton fiber and nitrocellulous fiber. Hospira is investigating to determine the root cause of the contamination. Sodium chloride injection is used to treat conditions such as dehydration and metabolic alkalosis, as a priming solution in hemodialysis procedures and blood transfusions, and to aid in the infusion of drug additives. If the ... Read More

Water and electrolyte solution recalled due to possible contamination

Tiny brass particles were found floating in a container of an injectable solution of water and electrolytes commonly used to treat conditions such as dehydration and metabolic alkalosis, as a priming solution in hemodialysis procedures and blood transfusions, and to aid in the infusion of drug additives. The brass particulate was identified as containing copper, zinc and lead. If a contaminated container of the solution is not detected it could cause a delay in therapy or, if administered, the solution containing brass particulate may result in occlusion of small blood vessels. In a worse-case scenario, copper toxicity could result in ... Read More

FDA places black box warning on Exjade

Exjade (deferasirox), a treatment for chronic iron overload due to blood transfusions for adults and children age 2 years and older, now has an Food and Drug Administration (FDA) black box warning alerting health care professionals and consumers of a risk of serious complications that may lead to death. A black box warning is the strongest form of warning issued by the FDA and is placed on drugs that have potentially harmful or deadly side effects. As a result of the FDA warning, new language was added to the drug’s Contraindications, Warnings and Precautions, and Drug Interactions sections of its ... Read More

FDA cautions about adverse events, deaths associated with anemia drug

The Food and Drug Administration (FDA) is notifying hemotology-oncology providers of an ongoing review of safety issues with Exjade (deferasirox), an oral medication used to treat patients aged 2 and older with chronic anemia and iron overload as a result of receiving blood transfusions. According to the early communication, new safety data suggests there may be a greater number of adverse events and deaths in patients using Exjade who are older than 60 years of age and who have myelodysplastic syndrome (MDS), a potentially fatal condition that can require frequent blood transmissions. Patients with MDS and other chronic anemias may ... Read More